AR084101A2 - Comprimido de carga de droga alta y proceso para su preparacion - Google Patents

Comprimido de carga de droga alta y proceso para su preparacion

Info

Publication number
AR084101A2
AR084101A2 ARP110104655A AR084101A2 AR 084101 A2 AR084101 A2 AR 084101A2 AR P110104655 A ARP110104655 A AR P110104655A AR 084101 A2 AR084101 A2 AR 084101A2
Authority
AR
Argentina
Prior art keywords
preparation
drug load
high drug
compressed high
tablet
Prior art date
Application number
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084101(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR084101A2 publication Critical patent/AR084101A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material

Abstract

Un comprimido que comprende 50 a 600 mg de la sal monomesilato del Compuesto I de fórmula (1) en una cantidad desde 30% hasta 80% en peso de la porción activa en base al peso total del comprimido; y proceso para su preparación.
ARP110104655 2002-04-23 2011-12-13 Comprimido de carga de droga alta y proceso para su preparacion AR084101A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0209265A GB0209265D0 (en) 2002-04-23 2002-04-23 Organic compounds

Publications (1)

Publication Number Publication Date
AR084101A2 true AR084101A2 (es) 2013-04-24

Family

ID=9935351

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP030101383 AR039335A1 (es) 2002-04-23 2003-04-22 Tableta de carga de droga alta
ARP090102074 AR072755A2 (es) 2002-04-23 2009-06-09 Comprimido de carga de droga alta del compuesto 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
ARP110104655 AR084101A2 (es) 2002-04-23 2011-12-13 Comprimido de carga de droga alta y proceso para su preparacion

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP030101383 AR039335A1 (es) 2002-04-23 2003-04-22 Tableta de carga de droga alta
ARP090102074 AR072755A2 (es) 2002-04-23 2009-06-09 Comprimido de carga de droga alta del compuesto 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida

Country Status (32)

Country Link
US (6) US20050267125A1 (es)
EP (1) EP1501485B1 (es)
JP (4) JP2005529126A (es)
KR (1) KR100728846B1 (es)
CN (2) CN1646103A (es)
AR (3) AR039335A1 (es)
AT (1) ATE374016T1 (es)
AU (1) AU2003229705C1 (es)
BR (1) BR0309528A (es)
CA (1) CA2483199C (es)
CY (1) CY1106996T1 (es)
DE (1) DE60316552T2 (es)
DK (1) DK1501485T3 (es)
ES (1) ES2290457T3 (es)
GB (1) GB0209265D0 (es)
GE (1) GEP20094627B (es)
HK (1) HK1073253A1 (es)
HR (1) HRP20040996B1 (es)
IL (1) IL164678A (es)
MX (1) MXPA04010496A (es)
MY (1) MY136406A (es)
NO (1) NO341027B1 (es)
NZ (1) NZ536046A (es)
PE (1) PE20031045A1 (es)
PL (1) PL199779B1 (es)
PT (1) PT1501485E (es)
RU (2) RU2363450C2 (es)
SI (1) SI1501485T1 (es)
TN (1) TNSN04213A1 (es)
TW (1) TWI350184B (es)
WO (1) WO2003090720A1 (es)
ZA (1) ZA200408441B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
PL1720853T3 (pl) 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
BRPI0608840B8 (pt) 2005-03-07 2021-05-25 Batyer Healthcare Ag composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
JP4733120B2 (ja) 2005-05-26 2011-07-27 大日本住友製薬株式会社 医薬品組成物
EP1762230B2 (de) * 2005-08-15 2016-04-20 Siegfried International AG Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
AU2007299764B2 (en) 2006-09-22 2011-10-13 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with Abl tyrosine kinase inhibitors
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2009042803A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Imatinib compositions
PE20091390A1 (es) 2007-11-06 2009-10-13 Novartis Ag Composiciones farmaceuticas de accion doble basadas en el bloqueo de los receptores de angiotensina y la inhibicion de la endopeptidasa neutral
CA2727737C (en) 2008-06-27 2016-08-23 Indiana University Research And Technology Corporation Materials and methods for suppressing and/or treating neurofibroma and related tumors
EP2370078A1 (en) 2008-12-01 2011-10-05 Novartis AG Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
PL234542B1 (pl) * 2010-06-21 2020-03-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób otrzymywania kompozycji farmaceutycznej zawierającej imatinib lub jego farmaceutycznie dopuszczalną sól
US20130085145A1 (en) * 2010-06-21 2013-04-04 Suven Life Sciences Limited Imatinib mesilate pharmaceutical tablet
EP2603288A1 (en) 2010-08-11 2013-06-19 Synthon BV Pharmaceutical granulate comprising imatinib mesylate
TR201010618A2 (tr) 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
CN102552268A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种含有α晶型甲磺酸伊马替尼的药物制剂
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
CN102349874B (zh) * 2011-08-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼组合物及其制备方法
CN102349875A (zh) * 2011-10-11 2012-02-15 浙江华海药业股份有限公司 甲磺酸伊马替尼片的制备方法
CA2853095A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
MX2014006201A (es) 2011-11-24 2014-12-05 Imuneks Farma Ilaç Sanayi Ve Ticaret A S Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
KR101428149B1 (ko) * 2011-12-23 2014-08-08 씨제이헬스케어 주식회사 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
GB201204810D0 (en) 2012-03-20 2012-05-02 Pharos Pharmaceutical Oriented Services Ltd Pharmaceutical compositions
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
RU2517216C2 (ru) * 2012-08-22 2014-05-27 Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД") Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
GB201304699D0 (en) 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
KR101520792B1 (ko) * 2013-04-10 2015-05-15 보령제약 주식회사 고부하 이매티닙 정제
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
CN104749226A (zh) * 2013-12-25 2015-07-01 辰欣药业股份有限公司 一种用电位滴定法测定甲磺酸伊马替尼含量的方法
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
CA3145658A1 (en) 2019-07-15 2021-01-21 Intas Pharmaceuticals Ltd. Pharmaceutical composition of imatinib.

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH176497A (de) 1934-09-14 1935-04-15 Schmid Ernst Alarmvorrichtung.
US3453368A (en) * 1966-01-13 1969-07-01 Hoffmann La Roche Smaller high potency compressed tablets of ascorbic acid
US3751277A (en) * 1971-03-24 1973-08-07 Dow Chemical Co Tablet coating process and composition
US4562024A (en) 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4639458A (en) 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3868077D1 (de) * 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
JPS63267731A (ja) * 1987-04-23 1988-11-04 Asahi Chem Ind Co Ltd 錠剤組成物
JPH03501967A (ja) 1987-07-22 1991-05-09 ヨハン・ヴィッゴ・ファーベル エイズの処置に有用なフシジン酸
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
DE4031881C2 (de) 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5635208A (en) 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
PT723777E (pt) 1993-10-12 2002-11-29 Mitsubishi Pharma Corp Comprimido contendo granulos entericos
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US5916593A (en) * 1994-09-22 1999-06-29 Akzo Nobel, N.V. Process of making dosage units by wet granulation
ES2079327B1 (es) 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5805889A (en) * 1995-10-20 1998-09-08 Sun Microsystems, Inc. System and method for integrating editing and versioning in data repositories
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
NZ330864A (en) 1996-02-29 2001-07-27 Fujisawa Pharmaceutical Co Beta-lactam antibiotic-containing tablet including a disintegrant and a binder
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
JP3212531B2 (ja) * 1997-03-21 2001-09-25 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、低置換度ヒドロキシプロピルセルロース崩壊剤及びその製造方法
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
AU750611B2 (en) 1997-11-17 2002-07-25 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
DE19758100B4 (de) * 1997-12-18 2006-05-04 Lichtwer Pharma Ag Verfahren zum Herstellen von Pflanzenextrakt enthaltenden pharmazeutischen Formulierungen
KR20010041609A (ko) 1998-03-06 2001-05-25 유란드 인터내셔날 에스.피.아. 속해성 정제
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CA2239931A1 (en) 1998-07-15 2000-01-15 Bernard Charles Sherman Pharmaceutical tablet comprising norfloxacin
CA2340054C (en) * 1998-08-12 2005-10-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
UA72483C2 (en) 1998-11-10 2005-03-15 Moxifloxacin-containing pharmaceutical preparation and method for its manufacture
US6498153B1 (en) * 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
IT1311907B1 (it) 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
US7182958B1 (en) 1999-08-03 2007-02-27 Lilly Icos Llc. β-carboline pharmaceutical compositions
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US6582721B1 (en) 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
JP2001139462A (ja) 1999-11-10 2001-05-22 Dai Ichi Seiyaku Co Ltd 新規製剤
CA2362816C (en) * 1999-12-08 2007-02-06 Pharmacia Corporation Valdecoxib compositions
CZ300558B6 (cs) 1999-12-09 2009-06-17 Reckitt Benckiser Healthcare (Uk) Limited Tabletová kompozice nesteroidního protizánetlivého léciva a zpusob její prípravy
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
DE10003757A1 (de) * 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
JP2003525229A (ja) 2000-03-03 2003-08-26 ランバクシー ラボラトリーズ リミテッド シプロフロキサシンを一日一回投与するための経口投与制御送給システム
ATE412413T1 (de) 2000-03-22 2008-11-15 Pharmacia & Upjohn Co Llc Oxazolidin tablettenformulierung
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
PE20020229A1 (es) 2000-04-12 2002-04-11 Novartis Ag COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE
CZ20024180A3 (cs) 2000-06-22 2003-04-16 Novartis Ag Pevné orální farmaceutické kompozice obsahující valsartan
JP4698000B2 (ja) 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
WO2002067993A1 (fr) 2001-02-27 2002-09-06 Senju Pharmaceutical Co., Ltd. Systeme de liberation de medicament de type polymere biodegradable
JP4429732B2 (ja) * 2002-04-10 2010-03-10 バージニア コモンウェルス ユニバーシティー 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NO20045072L (no) 2005-01-20
DE60316552D1 (de) 2007-11-08
ZA200408441B (en) 2005-08-31
GB0209265D0 (en) 2002-06-05
JP2005529126A (ja) 2005-09-29
KR20040101550A (ko) 2004-12-02
CY1106996T1 (el) 2012-09-26
US20150209291A1 (en) 2015-07-30
BR0309528A (pt) 2005-02-15
AR039335A1 (es) 2005-02-16
HRP20040996B1 (en) 2010-11-30
RU2405540C1 (ru) 2010-12-10
TW200404009A (en) 2004-03-16
GEP20094627B (en) 2009-03-10
CA2483199A1 (en) 2003-11-06
US20050267125A1 (en) 2005-12-01
CN1646103A (zh) 2005-07-27
TNSN04213A1 (en) 2007-03-12
JP2015143250A (ja) 2015-08-06
NO341027B1 (no) 2017-08-07
PL199779B1 (pl) 2008-10-31
TWI350184B (en) 2011-10-11
ATE374016T1 (de) 2007-10-15
WO2003090720A1 (en) 2003-11-06
EP1501485B1 (en) 2007-09-26
AU2003229705B2 (en) 2007-01-25
JP2010031019A (ja) 2010-02-12
NZ536046A (en) 2007-08-31
RU2363450C2 (ru) 2009-08-10
US20160101105A1 (en) 2016-04-14
US9011911B2 (en) 2015-04-21
JP2013079271A (ja) 2013-05-02
CA2483199C (en) 2010-08-17
AR072755A2 (es) 2010-09-22
US20100203133A1 (en) 2010-08-12
JP5752107B2 (ja) 2015-07-22
US20120177737A1 (en) 2012-07-12
PE20031045A1 (es) 2004-02-10
RU2004134323A (ru) 2005-08-10
CN101653424A (zh) 2010-02-24
PT1501485E (pt) 2007-12-18
IL164678A (en) 2014-02-27
AU2003229705C1 (en) 2017-09-07
IL164678A0 (en) 2005-12-18
MY136406A (en) 2008-09-30
KR100728846B1 (ko) 2007-06-14
JP5798269B2 (ja) 2015-10-21
MXPA04010496A (es) 2004-12-13
EP1501485A1 (en) 2005-02-02
ES2290457T3 (es) 2008-02-16
AU2003229705A1 (en) 2003-11-10
US20140135340A1 (en) 2014-05-15
HRP20040996A2 (en) 2005-06-30
DE60316552T2 (de) 2008-07-03
SI1501485T1 (sl) 2008-08-31
DK1501485T3 (da) 2007-12-27
HK1073253A1 (en) 2005-09-30
PL371495A1 (en) 2005-06-27

Similar Documents

Publication Publication Date Title
AR084101A2 (es) Comprimido de carga de droga alta y proceso para su preparacion
ES2655435T3 (es) Formulación de disolución rápida de cinacalcet
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
SV2008001369A (es) Benzimidazoles
EA200500891A1 (ru) Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
AR054382A1 (es) Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso
HRP20120004T1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
ECSP099501A (es) Formulaciones de dosis unitaria y métodos para el tratamiento de la trombosis con un inhibidor oral del factor xa
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
HK1096034A1 (en) A solid dosage form comprising a fibrate
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
CO5390076A1 (es) Composiciones farmaceuticas
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
PT1506185E (pt) Compostos novos e sua utilizacao
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
ATE386725T1 (de) Heterocyclylverbindungen
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
SE0102440D0 (sv) New compound

Legal Events

Date Code Title Description
FB Suspension of granting procedure